Related Experiment Video
Updated: Jun 17, 2026

Comparative Analysis of Human Growth Hormone in Serum Using SPRi, Nano-SPRi and ELISA Assays
Published on: January 7, 2016
Growth hormone therapy in Noonan syndrome: growth response and characteristics
1Queen Silvia Childrens Hospital, The Sahlgrenska Academy, University of Gothenburg, Goteborg, Sweden. otto.westphal@vgregion.se
Abstract:
Growth hormone treatment in Noonan syndrome increases growth velocity significantly during the first 2 years of treatment and, to some extent, until puberty. This increase is more pronounced if treatment is started at an early age. Treatment before the age of 5 years is not recommended due to an increased risk of malignancies. In contrast to other growth hormone-treated patients, a slight but significant further increase in height gain can be expected during pubertal growth (at least in boys). Final height improvement varies between 1 and 2 SDS in different studies. Cardiac function does not seem to be impaired during treatment. No significant adverse events have been reported.
Related Concept Videos
Nature and Nurture
Major Hormones and Their Functions
Oxytocin, produced in the hypothalamus and released by the pituitary gland, plays a role in social bonding, childbirth, and lactation.
Hypoglycemia and Glucagon
Signs of Puberty
Role of Hematopoietic Growth Factors
Thrombopoietin (TPO), mainly released by the liver,...
Cushing Syndrome II: Pathophysiology